- Home
- ATAI
as 03-31-2025 3:31pm EST
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
| Founded: | 2018 | Country: | Germany |
| Employees: | N/A | City: | BERLIN |
| Market Cap: | 291.5M | IPO Year: | 2021 |
| Target Price: | $9.00 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.03 - $2.85 | Next Earning Date: | 03-17-2025 |
| Revenue: | $308,000 | Revenue Growth: | -1.91% |
| Revenue Growth (this year): | -17.21% | Revenue Growth (next year): | 20.00% |
Stock Insider Trading Activity of ATAI Life Sciences N.V. (ATAI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Apeiron Investment Group Ltd. | ATAI | 10% Owner | Mar 24 '25 | Buy | $1.40 | 1,800,000 | $2,520,000.00 | 42,369,415 | |
| Johnson Anne Nagengast | ATAI | Chief Financial Officer | Mar 21 '25 | Sell | $1.35 | 33,545 | $45,285.75 | 140,045 | |
| Kirpekar Sahil | ATAI | Chief Business Officer | Mar 21 '25 | Sell | $1.35 | 48,563 | $65,560.05 | 115,636 | |
| Short Glenn Frank | ATAI | Chief Scientific Officer | Mar 21 '25 | Sell | $1.35 | 13,161 | $17,767.35 | 42,333 | |
| Craig Kevin James | ATAI | Chief Medical Officer | Mar 21 '25 | Sell | $1.35 | 11,563 | $15,610.05 | 8,437 | |
| Apeiron Investment Group Ltd. | ATAI | 10% Owner | Feb 14 '25 | Buy | $2.10 | 10,835,718 | $22,755,007.80 | 42,369,415 |
Latest ATAI Life Sciences N.V. News
ATAI Breaking Stock News: Dive into ATAI Ticker-Specific Updates for Smart Investing
TipRanks
9 days ago
Psychedelic: Exclusive talk with biotech company Clearmind Medicine
TipRanks
10 days ago
Psychedelic: atai Life Sciences, NRx report quarterly results
Simply Wall St.
13 days ago
Atai Life Sciences Full Year 2024 Earnings: Misses Expectations
GlobeNewswire
15 days ago
atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
TipRanks
17 days ago
Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial
GlobeNewswire
21 days ago
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
GlobeNewswire
a month ago
atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression
Insider Monkey
a month ago
Atai Life Sciences N.V. (ATAI): Among the Best Psychedelic Stocks to Buy in 2025
Compare ATAI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATAI ATAI Life Sciences N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.